- ONCOLOGIE & HEMATOLOGIE
DOMAINES THERAPEUTIQUES :
Bemarituzumab
anti-FGFR2b Antibody
Phase 1b/2
Monotherapy
Indication
Solid Tumors with
FGFR2b Overexpression
Solid Tumors with
FGFR2b Overexpression
A Phase 1b/2, multicenter, Open-label Basket Study evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression
Amgen protocol ID 20210104
Sotorasib
KRAS G12C Inhibitor
Phase 3
Combination therapy
platinum doublet
platinum doublet
Indication
NSCLC
NSCLC
Sotorasib platinum doublet combination versus pembrolizumab platinum doublet combination as a front-line therapy in participants with stage IV or advanced stage IIIB/C nonsquamous Non-Small Cell Lung Cancer, negative for PD-L1
Amgen protocol ID 20190341
Status Switzerland
Recruiting
Sotorasib
KRAS G12C Inhibitor
Phase 3
Combination therapy
FOLFIRI plus panitumumab or FOLFIRI w/wo bevacizumab
FOLFIRI plus panitumumab or FOLFIRI w/wo bevacizumab
Indication
mCRC
mCRC
Open-label, active-controlled study of Sotorasib, Panitumumab, and FOLFIRI versus FOLFIRI with or without Bevacizumab-awwb for treatment-naïve patients with metastatic colorectal cancer with KRAS p.G12C mutation
Amgen protocol ID 20210081
Status Switzerland
Recruiting
Centers, PIs:
USZ, R. Fritsch
USZ, R. Fritsch
Tarlatamab
(AMG 757)
(AMG 757)
DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 3
Monotherapy
Indication
LS-SCLC
LS-SCLC
A phase 3, randomized, double-blind, placebo-controlled, study evaluating tarlatamab after chemoradiotherapy in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Amgen protocol ID 20230016
Tarlatamab
(AMG 757)
(AMG 757)
DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 1b
Monotherapy
Indication
ES-SCLC
ES-SCLC
A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of subcutaneous Tarlatamab in subjects with Extensive Stage Small Cell Lung Cancer
Amgen protocol ID 20230298
Tarlatamab
(AMG 757)
(AMG 757)
DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 3
Combination therapy with Durvalumab
Indication
ES-SCLC
ES-SCLC
A study comparing tarlatamab in combination with durvalumab versus durvalumab alone in subjects with extensive-Stage Small-Cell lung Cancer following platinum, etoposide and durvalumab.
Amgen protocol ID 20200041
Status Switzerland
Recruiting
AMG 355
anti-CCR8 monoclonal antibody
Phase 1
Monotherapy and combination with Pembrolizumab
Indication
locally advanced
or metastatic solid tumors
locally advanced
or metastatic solid tumors
A Study of AMG 355 alone and in combination with Pembrolizumab in participants with advanced solid tumors
Amgen protocol ID 20220028
Status Switzerland
Recruiting
Centers, PIs:
KSSG, M. Jörger
IOSI, A. Stathis
KSSG, M. Jörger
IOSI, A. Stathis
AMG 193
MTA-Cooperative PRMT5 inhibitor
Phase 1, 1b, 2
Combination therapy
+/- Docetaxel
+/- Docetaxel
Indication
MTAP-deleted solid tumors
MTAP-deleted solid tumors
A Phase 1/1b/2 Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors
Amgen protocol ID 20210023
Status Switzerland
Recruiting
Xaluritamig
(AMG 509)
(AMG 509)
anti-STEAP1 XmAb
Phase 1
Mono- and combination therapy
Indication
mCRCP
mCRCP
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Amgen protocol ID 20180146
Status Switzerland
Recruiting
For further questions relating to the study programme, please contact Carine Bast